BE471025A - - Google Patents
Info
- Publication number
- BE471025A BE471025A BE471025DA BE471025A BE 471025 A BE471025 A BE 471025A BE 471025D A BE471025D A BE 471025DA BE 471025 A BE471025 A BE 471025A
- Authority
- BE
- Belgium
- Prior art keywords
- metal derivatives
- dissolving metal
- derivatives according
- solvent
- dissolving
- Prior art date
Links
- 229910052751 metal Inorganic materials 0.000 claims description 17
- 239000002184 metal Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 14
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 239000011787 zinc oxide Substances 0.000 claims description 5
- 229940105296 zinc peroxide Drugs 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 229910000510 noble metal Chemical class 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 150000002696 manganese Chemical class 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 2
- -1 manganese, halogen Chemical class 0.000 claims 2
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 claims 1
- 125000002081 peroxide group Chemical group 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 235000007258 Anthriscus cerefolium Nutrition 0.000 description 1
- 241000533415 Chaerophyllum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000003539 anti-scorbutic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G9/00—Compounds of zinc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE471025A true BE471025A (en, 2012) |
Family
ID=121018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE471025D BE471025A (en, 2012) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE471025A (en, 2012) |
-
0
- BE BE471025D patent/BE471025A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0593601B1 (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| CH629479A5 (fr) | Derives de la taurine, medicament contenant ces derives et procede de preparation de ces derives. | |
| EP0021940B1 (fr) | Nouveaux dérivés aminés du benzothiazole, leur procédé de préparation et leur application en thérapeutique | |
| EP0754173B1 (fr) | Procede de purification de la diacetylrheine | |
| BE471025A (en, 2012) | ||
| LU85716A1 (fr) | Procede de preparation d'un nouveau compose complexe d'hemine ayant des applications medicales | |
| FR2612399A1 (fr) | Compositions pharmaceutiques agissant sur le coeur et le systeme cardiovasculaire et procede pour leur preparation | |
| EP0086705A1 (fr) | Solution aqueuse d'acide ursodésoxycholique à usages thérapeutiques, son procédé de préparation et application au traitement des lithiases biliaires | |
| EP0073715A1 (fr) | Composés bromés utilisables dans des produits opacifiants | |
| CH637650A5 (fr) | Procede de preparation d'un acide chromone carboxylique. | |
| BE513723A (en, 2012) | ||
| LU85296A1 (fr) | Procede de preparation de derives de pyrimidinetrione | |
| CH411820A (fr) | Procédé de préparation de nouveaux composés hépariniques utilisables, notamment, pour le traitement des troubles de la coagulabilité sanguine | |
| BE582546A (en, 2012) | ||
| BE402029A (en, 2012) | ||
| BE666733A (en, 2012) | ||
| BE517035A (en, 2012) | ||
| BE546149A (en, 2012) | ||
| CH429719A (fr) | Procédé de préparation de nouveaux diamino stéroïdes | |
| BE445966A (en, 2012) | ||
| BE704075A (en, 2012) | ||
| BE509935A (en, 2012) | ||
| BE497785A (en, 2012) | ||
| FR2475546A1 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant | |
| CH106039A (fr) | Procédé pour transférer la vitamine soluble dans les corps gras (vitamine A), de la matière grasse qui la contient à ses solvants organiques. |